Related Experiment Video

Updated: Aug 29, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

Effects of high ticlopidine doses on platelet function in acute coronary syndrome patients

Patrick Bélanger1, Donald A Palisaitis, Jean G Diodati

  • 1Research Center, Hôpital du Sacré-Coeur de Montréal, and Faculty of Pharmacy, Université de Montréal, Montréal, Quebec, Canada.

Journal of Cardiovascular Pharmacology
|December 12, 2003
PubMed

Insights

Higher doses of ticlopidine (500 mg twice daily) combined with aspirin accelerate platelet inhibition in acute coronary syndromes. This faster platelet response is crucial for patients undergoing percutaneous coronary intervention.

Area of Science:

  • Cardiology
  • Pharmacology
  • Hematology

Background:

  • Acute coronary syndromes (ACS) require rapid management to prevent adverse events.
  • Platelet activation and aggregation are key contributors to ACS pathophysiology.
  • Percutaneous coronary intervention (PCI) with stent placement is a common treatment for ACS.

Purpose of the Study:

  • To evaluate if higher doses of ticlopidine with acetylsalicylic acid (aspirin) provide faster inhibition of platelet activation and aggregation in ACS patients.
  • To compare the efficacy of ticlopidine 250 mg versus 500 mg twice daily in this patient population.

Main Methods:

  • Seventeen ACS patients eligible for potential PCI were randomized.
  • Patients received either ticlopidine 250 mg or 500 mg twice daily for 5 days, alongside aspirin.
  • Platelet aggregation and activation were measured daily for 5 days.

Main Results:

  • Ticlopidine 500 mg twice daily significantly reduced platelet activation and aggregation compared to 250 mg twice daily after 2 days.
  • Mean platelet activation reduction was 17.6% (days 3-6) with the higher dose (P < 0.05).
  • Mean platelet aggregation reduction was 16.9% (days 3-6) with the higher dose (P < 0.05).

Conclusions:

  • Administering ticlopidine 500 mg twice daily with aspirin achieves faster and stronger platelet inhibition in ACS patients.
  • This higher dosage regimen may improve outcomes for ACS patients undergoing PCI.
Abstract

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation09:13

Turbidimetry on Human Washed Platelets: The Effect of the Pannexin1-inhibitor Brilliant Blue FCF on Collagen-induced Aggregation

Published on: April 6, 2017

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Transient Ischemic Attack l: Introduction01:26

Transient Ischemic Attack l: Introduction

A transient ischemic attack (TIA) is a brief episode of neurological dysfunction caused by a temporary, focal reduction in cerebral blood flow. Although symptoms resemble those of an ischemic stroke, the interruption in perfusion is short-lived and does not cause permanent infarction. TIAs are clinically important because they often serve as early warning events for future stroke.Mechanisms of Transient Cerebral IschemiaTransient cerebral ischemia may arise through several mechanisms. One...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...